Enanta Pharmaceuticals Inc (ENTA) Options

Time to SHINE! Giddy-up ENTA!

ENTA isn’t funded by the government.

When it rains, it pours... scratch one ENTA program:
https://share.newsbreak.com/ca8pnmw1?s=i16

Yes they both address “type 2” inflammatory conditions. Toxicity would be my concern but again I have read about cases treated with similar combinations of complementary drugs
The kit inhibitor also seems to have more on target toxicity and that’s why companies have discussed drug holidays for this class so I can also envision starting with a combination and continuing the stat 6/oral dupixent as a maintenance type therapy

ENTA has not explicitly mentioned combination therapy in immunology; however, with a little imagination one can construe slide #17 in the corporate slide to be highly suggestive of combination therapy.

ENTA’s latest corporate slide set (2/10/25):

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

The only changed slide relative to the 1/15/25 version of the slide set is on slide #18, which has an improved graphic to show the mammoth addressable market in immunology.

. I thought they did mention combo potential on imo in one of their call.

I don’t think they did and may not tomorrow since the drugs are a year apart and it’s a very niche indication I bring it up simply as a point of differentiation from the other players ahead of them.
They have mentioned combo for RSV in less common severe cases (interestingly if a patient did need an extended course of therapy they had a recent poster showing the N has a higher barrier to resistance than the L inhibitor class. They are the only N in the clinic as you know)

Yes, will see if tomorrow’s conference will bring more interest to the stock. I thought they did mention combo potential on imo in one of their call.

Agree, the market size of each of those potential indications are enormous- for sure, can have more than one or two winners there.

Not sure why $PFE is waiting for here.

I heard many say that kind of thing

But if you have no thinking and hoping, you are pretty much a dead people lol

It's no longer a request since shareholders approved the proposal (#msg-175939570). In any case, the additional 800K shares allocated to the Equity Incentive Plan is a minor matter in the overall scheme of things.

This looks like a Hale Mary approach. Ha! The definition of "hale" is strong and healthy.

"Still think this is the best risk reward investment out there, but that won’t make this kind of swings any easier to ignore 

Hope to see the deal before Summer here!"
For me, "Still think" and "Hope" are not investment metrics I incorporate into my investment model.

I would have thought THRD's poor showing in phase 1 would have been a positive for ENTA. BPMC now is the only company ahead of them with a what appears to be a clean drug so far w similar MOA

They are also behind in STAT6, but it seems only recludix has a traditional small molecule ahead of them by about a year (they at targeting entering phase 1 later this year I believe). KYMR is in phase 1 with a protein degrader so different approach to the target. Recludix is private but they did present recently and worth a listen IMO. (oppenhiemer feb https://recludixpharma.com/news-events/)

These are massive opportunities so should be room for more than one player IMO, and you never know when someone will stumble (THRD case in point)

ENTA is the only one that has both in house as far as I know so could be an opportunity to target the refractory cases that could benefit from a combination of the two drugs (complementary MOA). There is a precedent there are cases of dupixent refractory cases given second biologics like il-5 inhibitors for example

Enanta says that it "conducted years of discovery work on [the] hepatitis C virus" that it leveraged to "identify compounds for use in treating patients infected with the new coronavirus," later protected by a patent that Pfizer was accused of infringing.

"Pfizer challenged the … patent's priority date by seizing on the fact that [its provisional application's] specification contained a typographical error in its definition of [a] claim term," according to the brief from Enanta. "The court concluded that it could not 'correct' the typographical error … and that the … patent therefore contained 'new matter' such that it was not entitled to claim priority to the [provisional application]."

This was an issue over written description, says Enanta, which has to do with whether patents are described well enough to hold up in court. This "is a question of fact on which the jury should hear evidence and resolve any disputed facts," says Enanta. 

The lower court ruling was also a misreading of a different Federal Circuit ruling from 2003 in Novo Industries LP v. Micro Molds Corp., says Enanta. In that case, a Federal Circuit panel ruled that a Florida federal judge "lacked authority" to change the word "a" to mean "and," while handling claim construction in a patent lawsuit over window blinds. The court then established a two-part, so-called Novo Industries test to determine if judges could change words in patent claims.

"Since handing down Novo Industries in 2003, this [appeals] court has applied its two-part test for correcting errors in issued patents in ten cases," reads Friday's brief.

Enanta says Judge Casper was wrong to use the test because the Federal Circuit "has never held that Novo Industries applies to a district court's assessment of an error in a priority application."

"Novo Industries is a claim construction case. It has nothing to do with written description in a priority document" like a provisional application, says Enanta.

Read more at: https://www.law360.com/articles/2315049/drug-co-wants-fed-circ-to-undo-pfizer-covid-patent-win?copied=1

We have pretty much retraced all the gain since CEOs insider buy and the RSV partnership PR update, all in less than 20 trading days.

Still think this is the best risk reward investment out there, but that won’t make this kind of swings any easier to ignore

Hope to see the deal before Summer here!

The game plan is to keep the threat alive.

$PFE would be one of the potential buyer or partner soon, so no need to be too aggressive

This looks like a Hale Mary approach. Sure took their sweet time to file this too. 

March 25 - Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win

A Boston drug developer that lost its infringement case against Pfizer over the New York's company blockbuster Paxlovid Covid-19 treatment has told the Federal Circuit that a contentious issue regarding a typo in a patent document should have gone to a Jury.

(The essence stated above although a Subscription needed for full article.)

https://www.law360.com/florida/articles/2315049/drug-co-wants-fed-circ-to-undo-pfizer-covid-patent-win

Also - The patent covers "compounds and pharmaceutically acceptable salts [that] inhibit coronavirus replication activity," according to the Enanta lawsuit, ...

The wait is frustrating for sure. Especially now that the general market seems to have bottomed

You hope.

They need to show the street that they can close a deal and hopefully soon.

The wait is frustrating for sure. Especially now that the general market seems to have bottomed

Could be one news away from big gain

Pathetic stock performance and the company is requesting more incentive options be granted ?? The current management doesn’t deserve anymore in my opinion until they right this ship.

Baby FLO just up-chucked.........................

Just brutal. 

Vaccines are the new tobacco....

Only to the clueless.

Vaccines are the new tobacco....

Yeah, bumpy ride indeed, it should be worthwhile at the end.

And I don’t want to get off the ride and see a partnership or buyout news showing up right after

So I hold

Crazy swing over… I hope so. ENTA has been one bumpy ride. 🍀🍀🍀🍀

The volume is so low today
Less than 60k and only 1.5 hrs become close.

Maybe the crazy swing will be behind us soon, I hope

Some have likely reshorted the stock by now.

ENTA needs to execute and finalize an RSV or even an immunology deal. A major factor contributing to the negative asset value is the market’s lack of confidence in management’s execution.

On a POSITIVE note -

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Significant Decline in Short Interest

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,600,000 shares, a drop of 27.2% from the February 13th total of 3,570,000 shares. Based on an average trading volume of 562,300 shares, the short-interest ratio is presently 4.6 days. Approximately 13.1% of the company's shares are short sold.

https://www.marketbeat.com/instant-alerts/short-interest-in-enanta-pharmaceuticals-inc-nasdaqenta-decreases-by-272-2025-03-16/

Shorts appear to be back at it. Not one to often allege market manipulation but the pre-market action is unusually strange. Down $0.50 - it’s not a lot of shares but can see how some would be influenced. Hopefully we put in a solid bottom sooner than later.

the appropriate way to deal with that problem is to take corporate actions that raise the share price!

I agree.
But I can feel their pain too

At minimum, the stock should trade mid-teen, not single digit

The vote against was 26%, which is not out of line for these kinds of proposals. I voted my own shares against the proposal because I don't think management has earned the right to create any additional dilution beyond the shares already allocated to the Equity Plan. ENTA tried to justify the additional shares by noting that all stock options are underwater, but I think the appropriate way to deal with that problem is to take corporate actions that raise the share price!

In any event, I'm pretty confident in stating that the vote on the Equity Plan proposal was not a material factor in today's selloff.

Maybe someone is not pleased with the additional shares then. The Vote Against seems significant

Annual-meeting proposal to allocate an additional 800K shares to the 2019 Equity Incentive Plan passed:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000095017025040230/enta-20250313.htm

Added more. I remember feeling i should have added more when it ran to 7 then 8.7

I guess now it’s my chance ;)

For sure, buyout is my blue sky case too

But how would participating in an immunology conference translate to no buyout or even a delay on potential buyout?

Even if they are talking to someone about a buyout, they wouldn’t stop going to conferences unless they are really really close?

And I think the fact that the insider buy just happened recently - it should be well known we are not there yet

Sellers will regret big time when the deal is announced.

For now, I regret didn’t sell when shares are 40 percent higher few days ago

Agree but buyout potential is always part of the equation and if you move that probability down the stock can react. I could be totally wrong of course. I personally am ok w a reset based on how hot these preclinical assets are based in recent deal making and the number of early stage companies that have gotten funded in the space. I’ll take a buyout too! Still think RSV assets look very appealing

It would be silly if that’s the reason for the selloff as it should be well telegraphed by now they are going to be focus on immunology

Brutal. Investors despise it when companies do a do-over..

Yes
THRD data probably gives them some opening to differentiate only BPMC is ahead in the oral kit space w a clean molecule so far
My guess on sell off is less perception a buyout could be happening as they promote immunology

Sell off? Who knows. Management… secure deal / partner for the RSV assets and build shareholder value pls.

What’s up with the sell off?

Nice, i believe this is the first time ever they present in immunology focus conference.

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Mar 17, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 17, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-present-hc-wainwright-3rd-annual

They skipped almost all investor conferences this year except for one. At least they're participating in a medical conference.

Thanks Flo..

March 14 POSTERS Presentations:

A. EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSVRSV: Zelicapavir - Poster

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_EDP323-PKPD-Poster_KElmore-3.14.25.pdf

B. In Vitro Characterization of Respiratory Syncytial Virus Inhibitors RSV: Zelicapavir - Poster

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_InVitro-Characterization_MRhodin-3.14.25.pdf

C. A Phase-2 Double-Blind Placebo Controlled International Trial of Zelicapavir for Treatment of RSV in Young ChildrenRSV: Zelicapavir - Poster

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_Phase2-Zelicapavir-Poster_SHuang-3.14.25.pdf

D. First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV Results from a Phase 2a Human Viral Challenge Study RSV: EDP-323 -Presentation

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_EDP323-Oral-Pres_JDevincenzo-3.14.25.pdf

There will be an 8-K filing soon to announce the voting. The only issue of consequence is the company's proposal to allocate about 1M additional shares to the 2019 Equity Incentive Plan.